Schizophrenia and DSM-5: Diagnostic Criteria, Classification, and Updates

Schizophrenia in DSM-5

Schizophrenia is a chronic psychotic disorder classified under Schizophrenia Spectrum and Other Psychotic Disorders in DSM-5 (2013). The multiaxial system (Axis I–V) was eliminated in DSM-5. Diagnoses are now listed non-axially with specifiers.

Diagnostic Criteria (Criterion A: ≥2 for ≥1 month, at least one must be 1–3)

  1. Delusions
  2. Hallucinations
  3. Disorganized speech
  4. Grossly disorganized or catatonic behavior
  5. Negative symptoms (diminished emotional expression, avolition)

Criterion B: Social/occupational dysfunction for ≥6 months (includes prodromal/residual periods).

Criterion C: Exclude schizoaffective disorder, mood disorder with psychotic features, substance/medical causes.

Key DSM-5 Changes from DSM-IV

  • No subtypes (paranoid, disorganized, catatonic, undifferentiated, residual)—poor validity and reliability.
  • Catatonia: separate specifier (can apply to depressive, bipolar, medical conditions).
  • Dimensional assessment: severity ratings for 8 symptom domains (hallucinations, delusions, disorganized speech, abnormal psychomotor behavior, negative symptoms, impaired cognition, depression, mania).
  • Schizotypal personality disorder moved to this chapter (spectrum concept).

Related Diagnoses in the Chapter

  • Schizotypal personality disorder
  • Delusional disorder
  • Brief psychotic disorder
  • Schizophreniform disorder (1–6 months)
  • Schizoaffective disorder (mood episodes concurrent + psychotic symptoms without mood symptoms)
  • Substance/medication-induced psychotic disorder
  • Psychotic disorder due to another medical condition
  • Catatonia (associated with...)

Clinical Assessment

  • Structured interviews: SCID-5, CAARMS (at-risk), PANSS (severity).
  • Rule out: medical (encephalitis, autoimmune, metabolic, neoplastic), substance, mood disorders.
  • Neuroimaging (MRI) if atypical onset, focal signs, late onset.
  • Labs: CBC, CMP, TSH, B12/folate, RPR, HIV, toxicology, copper/ceruloplasmin (Wilson's), ANA.

Treatment Overview

  • Antipsychotics: Second-generation (risperidone, olanzapine, quetiapine, aripiprazole, lurasidone, cariprazine) first-line; clozapine for treatment-resistant (≥2 failed trials).
  • Psychosocial: CBTp, family psychoeducation, supported employment/education (IPS), ACT, cognitive remediation, social skills training.
  • Early intervention (CSC): Coordinated specialty care for first-episode psychosis → better outcomes.
  • Long-acting injectables (LAIs): Improve adherence, reduce relapse.

Prognosis

Heterogeneous. ~20% recover well; ~40% recurrent episodes with functional impairment; ~40% chronic disability. Early treatment, adherence, family support, and addressing social determinants improve trajectory.

Schizophrenia - Related Articles